Peptide Library

Human study PLS-00081

Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction.

Cross-sectional study · 40 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction.primary · International journal of cardiology · 2017-12-06 · PMID 29242099 · DOI

Design and participants

Design
Cross-sectional study
Population
Patients with recurrent angina and no structural coronary lesions undergoing coronary angiography and endothelial function testing, divided into normal endothelial function (n=20) and endothelial dysfunction (n=20)
Conditions
coronary endothelial dysfunction, recurrent angina without structural coronary lesions
Setting
Cardiac catheterization laboratory (coronary angiography with intracoronary acetylcholine testing)
Planned enrollment (registry)
Not reported
Enrolled
40
Randomized
Not reported
Completed follow-up
Not reported
Funding
Listed as Research Support, Non-U.S. Gov't; funder not specified in the record

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Lower circulating endogenous MOTS-c levels are associated with impaired coronary endothelial function in humans. MOTS-c improved endothelial function in rodent vessels in vitro, suggesting it is a potential therapeutic target in endothelial dysfunction.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Humans were not given MOTS-c; only endogenous plasma levels were measured, so the study offers no evidence on administration effects or safety.
    • abstract only: Only the abstract is available; full methods, effect sizes and analyses are not reported in the record.
    • small or imprecise: Only 40 patients (20 per group) were studied, limiting precision of the association estimates.
    • confounding: Cross-sectional association between plasma MOTS-c and endothelial function cannot establish causality; adjustment for confounders is not described.
    • inappropriate endpoint: The human outcome is a plasma biomarker association with endothelial function. No MOTS-c was administered and no clinical outcome was measured.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 29242099, abstract (Conclusion, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 29242099, abstract (Methods, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 29242099, title (publication types) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 29242099, abstract (Methods, sentences 3-4) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 29242099, abstract (Methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 29242099, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).